Ingrezza Use in Patients with Pacemakers and Atrial Fibrillation
Ingrezza (valbenazine) can be used in patients with pacemakers and atrial fibrillation, but requires baseline ECG assessment and careful monitoring for QT prolongation, particularly given the potential for additive QT effects with other medications commonly used in AF management.
QT Prolongation Risk
Ingrezza carries a specific cardiac electrophysiology concern that is directly relevant to your patient. The FDA label indicates that Ingrezza may cause QT interval prolongation, with the magnitude depending on metabolic factors 1. Specifically:
- In typical patients taking 60-80 mg doses, mean QT prolongation is 5.3-6.7 msec
- In CYP2D6 poor metabolizers or those taking strong CYP2D6/CYP3A4 inhibitors, QT prolongation increases to 9.6-11.7 msec 1
This is particularly important because many antiarrhythmic drugs used for AF management (amiodarone, sotalol, dofetilide) also prolong the QT interval, creating potential for additive effects.
Required Monitoring Protocol
Before Starting Ingrezza
Obtain a baseline 12-lead ECG to measure the QTc interval 2. The 2023 Canadian guidelines emphasize that when initiating a QT-prolonging drug in patients already receiving another QT-prolonging medication (which may include AF drugs), an ECG is indicated 2.
Key baseline assessments:
- Measure uncorrected QT interval - should be <450 ms 3
- Check serum potassium and magnesium - correct to potassium ≥4.0 mEq/L before starting 2, 4
- Assess renal function - affects electrolyte balance and drug clearance 2
- Review all concurrent medications for QT-prolonging potential (use www.crediblemeds.org) 2
During Treatment
Monitor ECG within the first 2 weeks after starting Ingrezza 4. The 2005 ACCP guidelines specifically recommend ECG monitoring "at least once in the first 2 weeks following discharge" when antiarrhythmic drugs are initiated, with more frequent monitoring if there is concern for QT prolongation 4.
Ongoing monitoring should include:
- Electrolytes (potassium, magnesium) regularly, especially if the patient is on diuretics 2
- ECG if any dose changes to Ingrezza or AF medications 2, 3
- Immediate ECG if patient develops palpitations, syncope, or presyncope
Risk Stratification Considerations
The 2023 Canadian guidelines provide a practical framework: increased risk for torsades de pointes occurs when QTc exceeds 500 ms or when a drug increases QTc by >60-70 ms 2. Your patient has multiple considerations:
Higher risk factors present:
- Already on potential QT-prolonging AF medications
- Possible electrolyte disturbances from diuretics (common in AF management)
- Pacemaker suggests underlying cardiac disease
Risk mitigation strategies:
- Consider whether an alternative to Ingrezza exists for the underlying indication (tardive dyskinesia or chorea)
- If proceeding, ensure optimal electrolyte repletion before starting
- Avoid combining with high-risk QT-prolonging drugs (sotalol, dofetilide) if possible 2
- Consider using rate control agents with lower QT risk (beta-blockers, diltiazem, verapamil) rather than rhythm control agents 5
Pacemaker-Specific Considerations
The presence of a pacemaker adds complexity but also provides some protection. Pacemaker-dependent patients require monitoring for 12-24 hours after any device manipulation 6, but the pacemaker itself can prevent bradycardia-related QT prolongation. However:
- The pacemaker does not protect against drug-induced torsades de pointes
- Ensure pacemaker is functioning properly before starting Ingrezza
- Verify adequate lower rate limit (typically ≥60 bpm) to prevent pause-dependent QT prolongation 2
Practical Algorithm
Baseline assessment:
- 12-lead ECG with QTc measurement
- Electrolytes (K+, Mg2+), renal function
- Review all medications for QT effects
- Confirm pacemaker function
Decision point:
- If QTc >500 ms: Do not start Ingrezza
- If QTc 450-500 ms: Proceed with extreme caution, consider alternatives
- If QTc <450 ms and electrolytes normal: May proceed with monitoring
Initiation:
- Start at lowest dose (40 mg)
- Ensure K+ ≥4.0 mEq/L, Mg2+ normal
- Repeat ECG within 1-2 weeks 4
Follow-up:
- If QTc increases >60 ms or exceeds 500 ms: Reduce dose or discontinue 2
- Monitor electrolytes monthly if on diuretics
- Repeat ECG with any medication changes
Critical Caveat
Women and elderly patients are at higher risk for acquired long QT syndrome 2. If your patient fits these demographics, monitoring should be even more intensive, and the threshold for discontinuation should be lower.